Yungjin Pharmaceutical’s next-generation oral treatment for chronic obstructive pulmonary disease (COPD), YPL-001, has been selected as a new cross-governmental drug development project.
On Feb. 23, Yungjin Pharm. announced that it concluded an agreement with the Korea Drug Development Fund (KDDF) for the development of YPL-001 via a Phase 2 clinical trial by the U.S. F.D.A.
With the agreement, Yungjin Pharm. will receive support from the KDDF to conduct a Phase 2a clinical trial of YPL-001,a candidate treatment for COPD, in cooperation with the U.S. F.D.A.
With the support of the Ministry of Trade, Industry and Energy from 2011 to 2014, Yungjin Pharm. has become the first Korean company to receive approval of an investigational new drug application for YPL-001 from the U.S. F.D.A., which has acknowledged the potential efficacy of the treatment with a Phase 1 clinical trial.
YPL-001 is an oral treatment that is potentially a first-in-class mechanism drug to increase the sensitivity of steroids. Also, the potential of the product is highly rated in the market, as it can in theory directly treat the cause of diseases for COPD patients and improve the safety and convenience of doses.
Ryoo Byung-hwan, CEO of Yungjin Pharm., said, “Based on the successful Phase 2a clinical trials in the U.S. F.D.A., we will push ahead with technology transfer to global pharmaceutical companies, including in the U.S., Europe, and Japan. Also, we will conduct joint clinical trials with them.”